Pilot Study of the Safety and Efficacy of Apremilast in Subjects With Moderate to Severe Alopecia Areata
Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
Alopecia areata is a medical condition, in which the hair falls out in patches. The hair can
fall out on the scalp or elsewhere on the face and body.
Alopecia areata is an autoimmune skin disease, which means that the immune system is
recognizing the hair follicles as foreign and attacking them, causing round patches of hair
loss. It can progress to total scalp hair loss (alopecia totalis) or complete body hair loss
(alopecia universalis). The scalp is the most commonly affected area, but the beard or any
hair-bearing site can be affected alone or together with the scalp. Alopecia areata occurs in
males and females of all ages, and is a highly unpredictable condition that tends to recur.
Alopecia areata can cause significant distress to both patients and their families.
In this study, the aim to assess the effects of a new treatment called apremilast in patients
with alopecia areata. A total of 30 patients will be included in the study, which will run
for a total of 52 weeks.